Experiments show promising results for a drug that could lead to a lasting treatment for millions of Americans with macular degeneration.
Researchers at the University of North Carolina School of Medicine today published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease.
“We believe we may have found an optimized treatment for macular degeneration,” said senior study author Sai Chavala, MD, director of the Laboratory for Retinal Rehabilitation and assistant professor of Ophthalmology and Cell Biology & Physiology at the UNC School of Medicine. “Our hope is that MDM2 inhibitors would reduce the treatment burden on both patients and physicians.”
The research appeared Sept. 9, 2013 in the Journal of Clinical Investigation.
As many as 11 million Americans have some form of macular degeneration, which is the most common cause of central vision loss in the western world. Those with the disease find many daily activities such as driving, reading and watching TV increasingly difficult.
Currently, the best available treatment for macular degeneration is an antibody called anti-VEGF that is injected into the eye. Patients must visit their doctor for a new injection every 4-8 weeks, adding up to significant time and cost.
“The idea is we’d like to have a long-lasting treatment so patients wouldn’t have to receive as many injections,” said Chavala. “That would reduce their overall risk of eye infections, and also potentially lower the economic burden of this condition by reducing treatment costs.” Chavala practices at the Kittner Eye Center at UNC Health Care in Chapel Hill and New Bern.
All patients with age-related macular degeneration start out with the “dry” form of the disease, which can cause blurred vision or blind spots. In about 20 percent of patients, the disease progresses to its “wet” form, in which abnormal blood vessels form in the eye and begin to leak fluid or blood, causing vision loss.
While anti-VEGF works by targeting the growth factors that lead to leaky blood vessels, MDM2 inhibitors target the abnormal blood vessels themselves causing them to regress — potentially leading to a lasting effect.
Chavala and his colleagues investigated the effects of MDM2 inhibitors in cell culture and in a mouse model of macular degeneration. They found that the drug abolishes the problematic blood vessels associated with wet macular degeneration by activating a protein known as p53. “p53 is a master regulator that determines if a cell lives or dies. By activating p53, we can initiate the cell death process in these abnormal blood vessels,” said Chavala.
The Latest on: Macular degeneration
- New tool to cut drug prices crimps patient choice: 2019 Medicare Guide on October 7, 2018 at 12:30 pm
Starting next year, Medicare Advantage plans will be able to add restrictions on expensive, injectable drugs administered by doctors to treat cancer, rheumatoid arthritis, macular degeneration and oth... […]
- Maher presents macular degeneration on October 5, 2018 at 10:30 am
Patricia Ruth Maher, local writer and a member and volunteer with A Little Help will present a free talk entitled “Macular Degeneration: Your Life is not Over!” at the First Presbyterian Church, 7 Pon... […]
- Sight Concern Worcestershire talk on coping macular degeneration on October 5, 2018 at 7:50 am
A TALK will give people advice on coping with sight problems in their daily lives. Sight Concern Worcestershire is holding a skills for seeing talk on Wednesday, October 24, starting at 2pm, at St Mar... […]
- Mediterranean diet may prevent age-related macular degeneration on October 4, 2018 at 8:01 pm
THURSDAY, Oct. 4, 2018 -- A Mediterranean-style diet might significantly reduce your risk of a major cause of blindness, a new study suggests. Poor diet is emerging as an important factor in the devel... […]
- Drug wars about macular degeneration on October 4, 2018 at 5:07 am
Bayer Plc v NHS Darlington Clinical Commissioning Groups (CCG) and others  EWHC 2465 (Admin) – read judgment This judicial review concerned whether it was lawful for NHS clinical commissioning g... […]
- Door County Eye Associates Offering New Macular Degeneration Service on October 3, 2018 at 10:01 pm
Dr. Eric Paulsen of Door County Eye Associates is among the first to offer the AdaptDx test to detect and monitor age-related macular degeneration (AMD), which is the leading cause of irreversible vis... […]
- Mediterranean diet cuts macular degeneration risk on October 1, 2018 at 9:10 pm
Age-related macular degeneration (AMD) is a degenerative eye disease that’s the leading cause of severe vision impairment in Australians aged over 40. It is also the leading cause of blindness in the ... […]
- Your eyes as you age: Tips to help reduce the risk of Age-related Macular Degeneration on October 1, 2018 at 3:21 am
Your eyes as you age: Tips to help reduce the risk of Age-related Macular Degeneration Brandpoint (BPT) Clarksdale Press Register (BPT) - Aging is a fact of life, so it’s important to understand how o... […]
- Age Related Macular Degeneration Market Estimating the Prevalence around the Globe a Systematic Review and Meta-analysis 2018-2023 on September 28, 2018 at 2:16 am
Market Research Future published a cooked research report on “Age-related Macular Degeneration (AMD) Market Research Report – By Major Industry Trends, Worldwide Disease Analysis, Major Segments and S... […]
- Use of drug Avastin to treat eye condition macular degeneration in Sussex supported on September 26, 2018 at 3:13 am
Tough questions asking whether to offer patients an ‘effective’ but unlicensed drug to treat sight loss have been made easier thanks to a High Court ruling. The governing bodies of five clinical commi... […]
via Google News and Bing News